Central Alberta Pain & Rehabilitation Institute, Lacombe, AB, Canada.
Vivo Cura Health, Calgary, AB, Canada.
Regen Med. 2021 Jul;16(7):619-628. doi: 10.2217/rme-2021-0001. Epub 2021 Jun 30.
Describe the safety and effectiveness of intra-articular bone marrow concentrate (BMC) injection to treat knee and/or hip osteoarthritis (OA) in a Canadian cohort. A total of 112 patients with refractory OA received a single intra-articular injection of BMC into their knee(s) and/or hip(s). Pain, disability and quality of life were prospectively assessed prior to and 3, 6 and 12 months post-injection. Outcome scores were significantly improved at all time points post-BMC injection with maximal improvement observed at 3-6 months. Improvements were unrelated to patient age, sex or radiographic OA severity. The complication rate was <2%. In this Canadian cohort, knee/hip OA treated with a single BMC injection resulted in significant improvements in pain, disability and quality of life and a low complication rate.
描述加拿大队列中关节内骨髓浓缩物（BMC）注射治疗膝关节和/或髋关节骨关节炎（OA）的安全性和有效性。共有 112 例难治性 OA 患者接受了膝关节和/或髋关节单次关节内 BMC 注射。在注射前、注射后 3、6 和 12 个月，前瞻性评估疼痛、残疾和生活质量。BMC 注射后所有时间点的结局评分均显著改善，在 3-6 个月时观察到最大改善。改善与患者年龄、性别或放射学 OA 严重程度无关。并发症发生率<2%。在这个加拿大队列中，膝关节/髋关节 OA 单次 BMC 注射治疗可显著改善疼痛、残疾和生活质量，且并发症发生率低。
